vs
Side-by-side financial comparison of DNA X, Inc. (SONM) and Spero Therapeutics, Inc. (SPRO). Click either name above to swap in a different company.
DNA X, Inc. is the larger business by last-quarter revenue ($16.2M vs $12.6M, roughly 1.3× Spero Therapeutics, Inc.). Spero Therapeutics, Inc. runs the higher net margin — 250.7% vs -29.3%, a 280.0% gap on every dollar of revenue. On growth, Spero Therapeutics, Inc. posted the faster year-over-year revenue change (24080.8% vs 7.9%). Over the past eight quarters, Spero Therapeutics, Inc.'s revenue compounded faster (847.7% CAGR vs 9.9%).
SONM vs SPRO — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.2M | $12.6M |
| Net Profit | $-4.8M | $31.5M |
| Gross Margin | 11.2% | — |
| Operating Margin | -24.5% | — |
| Net Margin | -29.3% | 250.7% |
| Revenue YoY | 7.9% | 24080.8% |
| Net Profit YoY | -89.2% | 250.9% |
| EPS (diluted) | $-4.83 | $0.56 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $12.6M | ||
| Q3 25 | $16.2M | $0 | ||
| Q2 25 | $11.2M | $0 | ||
| Q1 25 | $16.7M | $12.0K | ||
| Q4 24 | $15.3M | $52.0K | ||
| Q3 24 | $15.0M | $65.0K | ||
| Q2 24 | $11.5M | $114.0K | ||
| Q1 24 | $9.1M | $140.0K |
| Q4 25 | — | $31.5M | ||
| Q3 25 | $-4.8M | $-7.4M | ||
| Q2 25 | $-7.5M | $-1.7M | ||
| Q1 25 | $458.0K | $-13.9M | ||
| Q4 24 | $-21.6M | — | ||
| Q3 24 | $-2.5M | $-17.1M | ||
| Q2 24 | $-6.6M | $-17.9M | ||
| Q1 24 | $-2.9M | $-12.7M |
| Q4 25 | — | — | ||
| Q3 25 | 11.2% | — | ||
| Q2 25 | 7.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | -1.2% | — | ||
| Q3 24 | 28.2% | — | ||
| Q2 24 | 25.8% | — | ||
| Q1 24 | 31.8% | — |
| Q4 25 | — | — | ||
| Q3 25 | -24.5% | — | ||
| Q2 25 | -60.2% | — | ||
| Q1 25 | 3.9% | -122758.3% | ||
| Q4 24 | 55.3% | — | ||
| Q3 24 | -15.8% | -28604.6% | ||
| Q2 24 | -56.2% | -16720.2% | ||
| Q1 24 | -29.5% | -9987.1% |
| Q4 25 | — | 250.7% | ||
| Q3 25 | -29.3% | — | ||
| Q2 25 | -66.8% | — | ||
| Q1 25 | 2.7% | -115550.0% | ||
| Q4 24 | -141.6% | — | ||
| Q3 24 | -16.7% | -26380.0% | ||
| Q2 24 | -57.5% | -15668.4% | ||
| Q1 24 | -31.9% | -9049.3% |
| Q4 25 | — | $0.56 | ||
| Q3 25 | $-4.83 | $-0.13 | ||
| Q2 25 | $-0.79 | $-0.03 | ||
| Q1 25 | $0.08 | $-0.25 | ||
| Q4 24 | $-116.99 | — | ||
| Q3 24 | $-9.32 | $-0.32 | ||
| Q2 24 | $-1.41 | $-0.33 | ||
| Q1 24 | $-0.65 | $-0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.1M | $40.3M |
| Total DebtLower is stronger | $5.1M | — |
| Stockholders' EquityBook value | $-701.0K | $59.0M |
| Total Assets | $40.2M | $68.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $40.3M | ||
| Q3 25 | $2.1M | $48.6M | ||
| Q2 25 | $2.0M | $31.2M | ||
| Q1 25 | $2.1M | $48.9M | ||
| Q4 24 | $5.3M | $52.9M | ||
| Q3 24 | $9.1M | $76.3M | ||
| Q2 24 | $9.6M | $63.5M | ||
| Q1 24 | $9.3M | $82.3M |
| Q4 25 | — | — | ||
| Q3 25 | $5.1M | — | ||
| Q2 25 | $2.9M | — | ||
| Q1 25 | $2.8M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $59.0M | ||
| Q3 25 | $-701.0K | $26.5M | ||
| Q2 25 | $-1.3M | $32.8M | ||
| Q1 25 | $-1.1M | $33.8M | ||
| Q4 24 | $-5.7M | $46.1M | ||
| Q3 24 | $15.3M | $65.5M | ||
| Q2 24 | $17.5M | $80.5M | ||
| Q1 24 | $19.8M | $96.2M |
| Q4 25 | — | $68.9M | ||
| Q3 25 | $40.2M | $54.2M | ||
| Q2 25 | $36.1M | $62.1M | ||
| Q1 25 | $36.0M | $77.7M | ||
| Q4 24 | $39.7M | $110.5M | ||
| Q3 24 | $49.1M | $135.2M | ||
| Q2 24 | $45.9M | $149.9M | ||
| Q1 24 | $42.4M | $167.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-7.0M | $-8.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | -0.26× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-8.4M | ||
| Q3 25 | $-7.0M | $17.4M | ||
| Q2 25 | $-4.9M | $-17.7M | ||
| Q1 25 | $-9.6M | $-4.0M | ||
| Q4 24 | $-4.5M | $-23.4M | ||
| Q3 24 | $-417.0K | $12.8M | ||
| Q2 24 | $-3.4M | $-18.7M | ||
| Q1 24 | $-168.0K | $5.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-4.5M | — | ||
| Q3 24 | $-554.0K | — | ||
| Q2 24 | $-3.4M | — | ||
| Q1 24 | $-198.0K | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -29.6% | — | ||
| Q3 24 | -3.7% | — | ||
| Q2 24 | -29.8% | — | ||
| Q1 24 | -2.2% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 0.9% | — | ||
| Q2 24 | 0.3% | — | ||
| Q1 24 | 0.3% | — |
| Q4 25 | — | -0.26× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -20.97× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
